CTOs on the Move

Y-mAbs Therapeutics

www.ymabs.com

 
YmAbs has a powerful set of capabilities for the development of biologics. Our product development team includes some of the most talented and experienced professionals in the antibody industry.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.ymabs.com
  • 750 Third Avenue 9th Floor
    New York, NY USA 10017
  • Phone: 212.847.9841

Executives

Name Title Contact Details

Funding

Y-mAbs Therapeutics raised $30M on 11/29/2017
Y-mAbs Therapeutics raised $115M on 02/17/2021

Similar Companies

Peptimmune

Peptimmune, Inc. is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Aro Biotherapeutics

Based in Philadelphia, Aro Biotherapeutics is a biotechnology company pioneering the development of tissue-targeted genetic medicines with a platform based on a proprietary protein technology called Centyrins. The company is developing a wholly-owned pipeline of Centyrin-based therapeutic candidates and is working with industry partners to leverage Centyrins for tissue-specific targeting of therapeutics for a diverse set of diseases.

Asher Bio

Asher Bio is a biotechnology company developing precisely targeted immunotherapies for cancer and other diseases.

Mason District Hospital

Mason District Hospital is a Havana, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

CellGenix

CellGenix is a leading global supplier of high quality raw and ancillary materials for the expanding market of cell and gene therapy and regenerative medicine. CellGenix develops, manufactures and markets human cytokines, growth factors, and other recombinant cell culture components in preclinical and GMP quality as well as proprietary serum-free media for further manufacturing of ATMPs. As a former ATMP developer and manufacturer, in more than two decades CellGenix gained in-depth cell processing knowledge and superior regulatory expertise. With this unique background, CellGenix understands the high requirements their customers are facing during product development and the regulatory approval process. To meet the increasing demand of GMP quality raw materials for ATMP manufacturing CellGenix has recently expanded manufacturing capacity, built additional R&D and QC laboratories, and warehouse space. The upgrade also introduced state-of-the-art, automated, large-scale capacities for recombinant protein products in the existing GMP facilities. CellGenix is headquartered in Freiburg, Germany and operates a subsidiary near Boston in Portsmouth, USA.